Skip to content

Investigation of the Cerebrospinal Fluid and Further Tissue Samples for Biomarker Indicating Spinal Ischemia and Organ Failure in Patients With Thoracoabdominal Aortic Aneurysm

Investigation of the Cerebrospinal Fluid and Further Tissue Samples for Biomarker Indicating Spinal Ischemia and Organ Failure in Patients With Thoracoabdominal Aortic Aneurysm

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03093857
Acronym
TAAA
Enrollment
100
Registered
2017-03-28
Start date
2014-06-01
Completion date
2018-12-31
Last updated
2017-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracoabdominal Aortic Aneurysm

Brief summary

Patients with a thoracoabdominal aortic aneurysm in need of an endovascular or open operative restructuring will be asked to participate in this study. After obtaining written consent a central venous catheter and a liquor drainage will be routinely placed during surgery. The catheter and the drainage will stay in the patients for at least 72 hours postoperatively. In total, nine measurements of the liquor and serum will be performed within a week in order to determine the following parameters: neuropeptide P, neuropeptide Y, neurofilament triplet protein (NFL), S100B, glial fibrillary protein (GFAp), lactate, glucose, or oxygen.

Detailed description

Patients with complex aortic diseases receiving an operative treatment are under risk of spinal cord damage due to insufficient blood circulation of the spinal cord during surgery. The risk depends on comorbidities, extent of surgery, and the perioperative management. Despite an adequate preoperative imaging, assessment of the blood circulation of the spinal cord during endovascular or open operative restructuring is struggling. Beside the monitoring possibilities of the spinal cord functions during surgery, insufficient approaches regarding early detection of spinal ischemia by using laboratory parameters exist. Several biomarker, e.g. neuropeptide P, neuropeptide Y, neurofilament triplet protein (NFL), S100B, glial fibrillary protein (GFAp), lactate, glucose, or oxygen, will be evaluated singularly or as a bundle of markers in small patient groups. Surgeries of thoracoabdominal aortic aneurysms are associated with high risks despite already existing high standardized procedures (Cowan et al. 2003). The major complications are cardiovascular, renal, pulmonary, gastrointestinal complications, and ischemias of the spinal cord. Especially, the ischemia of the spinal cord is a feared complication caused by the irreversibility and the small time frame. During the study samples of liquor and tissues (serum, urine) will be drawn pre-, peri- and postoperatively. Patients will receive a routinely placed liquor drainage due to the temporal duration in surgery. The liquor drainage stays in the patient also in the early postoperative phase. Hence, the patient will not be bothered with additional examinations. Additionally, biomaterial (blood) will be drawn routinely and used for the biomarker measurement as well as biobanking.

Interventions

DIAGNOSTIC_TESTDetermination of biomarker

Liquor, blood, and urine samples will be drawn and measured at different time points.

Sponsors

RWTH Aachen University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* presence of thoracoabdominal aortic aneurysm * endovascular or open operative restructuring * age\>18 years * given written consent * subjects, who are mentally and legally capable to understand the scope of the trial and comply with the protocol

Exclusion criteria

* local skin infection (cutaneous fungus, acne) * pregnant or lactating females * parallel participation in another clinical trial * incarcerated subjects * subjects, who are in an interdependency with the sponsor or investigator

Design outcomes

Primary

MeasureTime frame
Change in Glial fibrillary acidic protein (GFAp)baseline and postoperative day 1 and postoperative day 2 and week 1
Change in neuropeptide Pbaseline and postoperative day 1 and postoperative day 2 and week 1
Change in neuropeptide Ybaseline and postoperative day 1 and postoperative day 2 and week 1
Change in neurofilament triplet protein (NFL)baseline and postoperative day 1 and postoperative day 2 and week 1
Change in S100Bbaseline and postoperative day 1 and postoperative day 2 and week 1
Change in lactatebaseline and postoperative day 1 and postoperative day 2 and week 1
Change in glucosebaseline and postoperative day 1 and postoperative day 2 and week 1
Change in oxygenbaseline and postoperative day 1 and postoperative day 2 and week 1

Countries

Germany

Contacts

Primary ContactElena Hristodorova, MSc.
0241 80 35226

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026